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In Brief
Eliciting protective immunity against influenza remains a major challenge. Bajic et al. show how hemagglutinin (HA) hyperglycosylation can restrict the resulting antibody repertoire to an occluded epitope at the HA head interface. These antibodies protect against influenza-virus challenge, providing insights into antigen engineering to alter antibody responses.
INTRODUCTION
An outstanding question in adaptive immunity is why particular epitopes on an antigen are preferentially targeted by antibodies (Abs); moreover, why the magnitude and genetic diversity of the elicited antibody response vary among epitopes on a complex antigen. This phenomenon, better known as immunodominance, represents a significant hurdle for next-generation vaccines against rapidly evolving pathogens such as influenza and HIV. Indeed, analyses of antibody repertoires elicited against influenza hemagglutinin (HA) and HIV envelope (Env) glycoproteins, both major targets of the adaptive immune response, show that the immunodominant responses often target variable epitopes, which mutate readily to allow pathogen escape (Wrammert et al., 2008) . The broadly protective responses are generally subdominant, target conserved epitopes, such as a receptor-binding site (RBS), with limited variability because of functional constraints, and often show restricted gene usage (Petrova and Russell, 2018) . Thus, we need to understand the molecular correlates of immunodominance, in order to meet the challenge of directing immune responses away from antigenically variable epitopes to ordinarily subdominant but less variable and more broadly protective ones.
Strategies to alter patterns of immunodominance often focus on rational immunogen design approaches aimed at eliciting broadly neutralizing antibodies (bnAbs) (Correia et al., 2014; Haynes et al., 2012; Jardine et al., 2015; Mascola and Haynes, 2013) . A substantial number of bnAbs have been identified targeting conserved, subdominant epitopes on viral envelope glycoproteins. For both influenza HA and HIV Env, bnAbs have been isolated that target the conserved viral RBS as well as the membrane proximal region (MPER) in gp41 and an equivalent so-called ''stem'' region of HA (Corti et al., 2011; Ekiert et al., 2012; Krause et al., 2011; McCarthy et al., 2018; Schmidt et al., 2015b) . Several different approaches have been taken to engineer immunogens that selectively present these and other conserved epitopes. For example, computational design approaches have produced novel scaffolds that present a single alpha helix derived from HIV and respiratory syncytial virus (RSV) glycoproteins (Correia et al., 2014; Ofek et al., 2010) . Deconstructing the viral glycoprotein into domain-only fragments has yielded candidate immunogens containing the subdominant epitope(s) (Krammer and Palese, 2015) . The underlying premise of these strategies is to entirely remove the immunodominant epitope(s) from the immunogen, in order to elicit broadly neutralizing responses focused on conserved but subdominant epitopes.
An alternative approach for changing immunodominance is to shield immunodominant epitope(s). Viral evolution has naturally explored introducing or removing glycans to reduce or evade host adaptive immune responses (Lavie et al., 2018; Watanabe et al., 2018) . On one extreme, HIV Env protein has an average of 25 glycans per subunit, accounting for nearly half of its molecular mass, thus creating a so-called ''glycan shield'' , while flaviviruses, like dengue, have only one or two conserved glycans per subunit (Modis et al., 2003 (Modis et al., , 2005 . Influenza HA has a more varied glycosylation profile, depending on the subtype, which ranges between 7 and 14 glycans per polypeptide chain of the HA 0 precursor. Thus, for those viruses whose glycoproteins are hypoglycosylated, increasing glycan density may direct immune responses to subdominant epitopes and provide insight into how antibody repertoires change in response to glycosylation. We used influenza HA as a model antigen to query the impact of its altered glycosylation profile onto the amplitude and focus of host immune responses. We found that glycan shielding, believed to be responsible for poor immunogenicity of many pathogens and vaccine candidates including HIV Env, had no significant impact on the amplitude of humoral immune responses The total number of glycans for each construct is noted. See also Figure S1 .
including serum antibody and germinal center (GC) reactions. In contrast to wild-type (WT) HA, the hyperglycosylated HAs elicited restricted V H -gene responses, reminiscent of hapten-induced ones. Of these restricted responses, we discovered a class of subdominant Abs targeting a conserved, occluded epitope that becomes dominant after hyperglycosylation. We show that an antibody from this class did not neutralize in vitro but conferred complete protection in vivo after a lethal influenza challenge. These data show that glycan engineering of a viral antigen can change patterns of immunodominance and focus immune responses to broadly protective epitopes often occluded in the native protein oligomer.
RESULTS

Design and Characterization of Glycan-Modified Hemagglutinins
We took the following approach to identify potential sites for glycan modification using H3 Hong Kong/1/1968 (HK-68) HA from group 2 influenza as the template. We analyzed H3s circulating in the human population since 1968 and identified native, putative N-linked glycosylation sites (PNGs) on HA that could be engineered into HK-68. While circulating H1s have maintained an average of 8 PNGs since 1977, H3s have doubled the number of PNGs from 7 to 14 during their evolution in humans from 1968 to the present ( Figures 1A and 1B) . After glycan modeling of these native PNGs and identifying potential ''glycan holes,'' we added non-native PNGs. Implementing these approaches resulted in three glycan-modified hemagglutinins (gHAs): gHA RBS , gHA cRBS , and gHA shield . The first has an exposed RBS. The second has an additional PNG that prevents RBS-directed Abs from binding (''concealed'' RBS: cRBS) . The third creates a glycan ''shield'' covering all surface-exposed epitopes ( Figures  1C-1E ). We expressed all constructs in mammalian cells to ensure complex glycosylation. Successful glycan addition was assayed by loss of reactivity to a panel of conformational-specific Abs, HC19, HC45, and FI6, whose epitopes overlap some of the engineered PNGs ( Figure S1 ). . Since gHA cRBS and gHA shield blocked binding of the RBS-directed HC19, the observed reactivity was probably to an epitope, or epitopes, outside the canonical RBS-directed Ab footprint. To complement our serological characterization, we assessed the reactivity of individual GC B cells isolated post immunization, using our single-cell Nojima culture system. By screening culture supernatants from each gHA immunization against the other three gHAs and WT HK-68, we found that the single-B cell reactivity profiles validated our epitope masking strategy: only a handful of GC B cell clones elicited by WT HK-68 immunization bound either of the gHA immunogens (Figures 3A and S3A) . More importantly, while elicited by increasingly glycosylated HA immunogens, all of the responding GC B cells still bound the WT HK-68 ( Figures 3B-3D and S2B-S2D). These data indicate that no glycan-specific responses were elicited by gHAs and that the gHA responses targeted hitherto undescribed, common HA epitopes. Furthermore, the gHAs elicited equally robust GC and plasmablast responses (Figures S2E and S2F) . Thus, increasing the number of glycans on HA trimers did not impair the overall magnitude of humoral responses in mice.
Immunogenicity of Glycan-Modified Hemagglutinins
Genetically Restricted V H -Gene Usages in Responses to GlycanModified Hemagglutinins
We previously found that complex antigens, such as an HA from group 1 H1 Solomon Islands/03/2006 (H1 SI-06), elicited genetically diverse, unrestricted GC B cell responses (Kuraoka et al., 2016) ; complex antigens thus differ from haptens, which often produce stereotyped immune responses. Consistent with this observation, immunization with group 2 WT HA H3 HK-68 similarly elicited a genetically diverse and non-stereotyped response ( Figure 4A ). In contrast, however, the V H -gene usage narrowed dramatically upon immunization with the gHAs, selectively enriching for three V H genes: 1-69, 1-9, and 5-9-1 ( Figures  4B-4D ). V H 1-9 accounted for approximately 50% of the isolated, single-GC B cell-derived Abs to both gHA RBS (37/69) ( Figure 4B ) and gHA cRBS (39/81) ( Figure 4C ), but was absent from the response to WT HK-68 HA and reduced to 7% (4/56) in gHA shield ( Figure 4C ). Of the isolated V H 1-9 Abs, a substantial number were clonally related as determined by the relatedness of their heavy chain complementarity-determining region 3 (CDR H3); we identified a total of 9 unique lineages, with the largest clone containing 20 members from gHA cRBS immunization. V H 1-69 was the next most abundant gene segment in the responses to gHA RBS and gHA shield ; the frequency of this response in animals receiving the hyperglycosylated HAs was also greater than its level in the response to WT HA HK-68. We identified 9 lineages and 5 orphan Abs from this gene family. Lastly, V H 5-9-1 accounted for 10% of the gHA RBS and gHA shield responses and paired with the rare lambda-light chain; this gene usage increased in frequency from 0.7% (1/137) in response to WT HK-68 HA immunization. These data show that glycan-modified HAs elicited greatly enhanced frequencies of preferred V H -gene usages. Figure S3B ). Because all Abs elicited by the gHA immunizations bind WT HA HK-68, these data suggest that, while the epitope may include glycan interactions, antibody binding did not depend critically on the introduced glycans. We tested V H 5-9-1 Abs, 8H10 elicited by the WT HK-68 immunization, and FL-1066 from gHA shield immunization, for binding against a panel of historical H3 HAs spanning over 30 years of antigenic drift. We found that 8H10 and FL-1066 were broadly reactive with historical H3s; additionally, both Abs bound a representative H4 ( Figure S4A ).
Reactivity Profiles and Epitope Mapping of Stereotyped V H -Gene Responses
V H 5-9-1 Abs Recognize an Ordinarily Occluded Epitope
We determined crystal structures of three V H 5-9-1 Abs ( Figure S5 ). Thus, most of the epitope is occluded on a pre-fusion structure of an HA trimer. The antigen-combining site included contributions of both the heavy-and the light-CDR loops. The interaction interface was largely hydrophobic and the main interfacing amino-acid residues on HA were Pro221 and Trp222 (Pro217 and Trp222 on an H4). On the antibody side, the CDRs provided aromatic side-chain residues that sandwiched the HA Pro221 and Trp222 in a hydrophobic cleft between the light-and the heavy-chain CDRs ( Figures 5A-5C ). The conservation of this tryptophan between historical H3s and H4 helps explain, in part, the broad reactivity of these V H 5-9-1 Abs. Because of the occluded nature of the epitope, we performed cell surfaceexpressed H3 and H4 HA binding by flow cytometry (Figures S4B and S4C) and to intact H3 virions ( Figure S4D ). Both assays confirmed that these Abs can indeed engage an intact trimeric HA.
V H 5-9-1 Abs Are Non-neutralizing but Confer Fc-Dependent Protection In Vivo We carried out in vivo protection studies in mice to determine if V H 5-9-1 Abs could mediate protection against a lethal challenge were harvested and screened for binding in a Luminex-based assay. The binding signal to the immunizing antigen (x axis) was compared to the other three HA immunogen constructs (y axis). The coefficient of determination (R 2 ) of a linear regression fit is reported. n = number of monoclonal Abs from supernatants used in screening. See also Figure S3 .
with influenza viruses. Passive transfer of a murine IgG1 version of 8H10 conferred limited protection against 53 LD 50 intranasal challenge by H3N2 X31 (Figures 6A and 6B ), but the murine IgG2c version of 8H10 conferred complete protection against the same challenge regimen. The results indicate that an Fcdependent mechanism was responsible for protection. This observation is consistent with a lack of in vitro neutralizing activity against H3N2 in a microneutralization assay with 8H10 ( Figure 6C ).
DISCUSSION
We showed here that host immune responses can be manipulated through altering glycan density on influenza HA. We discov- Figure S4 . ered a class of V H 5-9-1 restricted Abs that recognized a conserved, cryptic epitope of influenza HAs. These clonally unrelated Abs converged in their mode of antigen recognition and bound the occluded HA epitope in a similar fashion. These V H 5-9-1 Abs were broad within the H3 subtype, from which the gHA immunogens are based, but also recognized the potentially pre-pandemic H4 subtype. While a representative antibody from this class did not neutralize in vitro, it did protect mice against lethal challenge with an H3 subtype virus in an Fc-dependent manner. An objective of this study was to use glycan engineering to focus the murine response to the RBS. The gHA
RBS
, with an exposed RBS, did not significantly increase RBSdirected responses however, and it appears that this site remained poorly immunogenic in mice and could not be elevated to dominance. In humans, the RBS is an immunogenic site that in principle can elicit bnAbs, within a group (e.g., CH65 [Whittle et al., 2011] ) and in some cases, across groups (e.g., K03.12 , C05 ). Many of these human RBS-directed Abs engage the RBS through a relatively long CDR H3. Thus, a possible explanation for the failure to boost ''canonical'' RBS-directed Abs is that the average length of the CDR H3 in mice is 2-3 amino-acid residues shorter than in humans.
Pathogens use a variety of different mechanisms to subvert and avoid host immune surveillance. Chronic human pathogens such as HIV and hepatitis C viruses actively alter their glycoprotein glycan profiles to evade host immune recognition. A parallel can be made with influenza viruses if we consider them as chronic infections on the population level. The self-masking of the HIV Env through its glycan shield is thought to be a critical issue in eliciting bnAbs. Indeed, decoration (e.g., Sabouri et al., 2014; Reed et al., 2016) of foreign proteins with ''self'' glycans is widely thought to control immunogenicity such that only particulate antigens can activate humoral responses. However, we show that hyperglycosylating HA to create an equivalent glycan shield had no measurable effect on the overall magnitude of the primary serum Ab and GC responses. With no loss of immunogenicity, even the gHA shield resulted in a redirection of specificity using restricted-gene usage. In short, the number of available epitopes did not appear to define the magnitude of humoral responses-an underlying assumption of the glycan shield model. Immunogen design approaches for HIV have attempted to leverage glycosylation to selectively elicit bnAbs by removing glycans on HIV Env to expose epitopes targeted by bnAbs. The data presented here show seemingly the converse: adding glycans on influenza HA can change patterns of immunodominance and elicit broadly protective Abs. The template antigen in this study was the hypoglycosylated HK-68 HA and many of the engineered PNGs in our gHA immunogens derived from a naturally circulating, highly glycosylated H3 from 2011 (H3 Victoria/361/2011). An open question is whether, in the human population, those individuals exposed to circulating H3s since 2011 might have a higher frequency of Abs targeting the occluded epitope identified here (Watanabe et al., 2019) .
How might the data from this study inform influenza vaccine strategies? Current immunogen design strategies for a universal influenza vaccine have focused primarily on how to elicit the subdominant, stem-directed Abs (Krammer and Palese, 2015) . Like the murine Abs described here, human stem-directed Abs are also genetically restricted (primarily V H 1-69, in humans) and protect mice by Fc-dependent mechanisms. The similar properties of Abs directed at the head interface and the stem suggest that both may be useful components of a universal influenza vaccine; the hyperglycosylation strategy described here might be such an approach. Thus, by integrating immunogen design strategies that elicit both Fc-dependent (e.g., stem and/or head-interface) and neutralizing-(e.g., RBS) directed responses may lead to a broadly protective vaccine. The purpose of this study was to understand if there was an underlying, deterministic principle that dictates the immunodominance hierarchy. Our findings are that the magnitude of humoral responses, including serum antibody and the GC reaction, are little affected by a glycan shield. That is to say, the magnitude of overall humoral responses appears insensitive to the numbers of available epitopes on an immunogen. This observation suggests that the low immunogenicity of HIV and other variable antigens is not a consequence of ''self-glycans'' obscuring epitopes but rather other mechanisms (e.g., active The top panels show the overall structures and indicate the immune focusing to a common epitope. The middle panels highlight the Fab footprints on HA and antibody CDR loops involved in binding. Contacts made by the CDR loops are detailed in the bottom panels. Essential HA residues are underlined. See also Figure S5 ; Table S1 . impairment of components of the immune system and host mimicry). Better understanding of this phenomenon can help focus and direct immune responses to desired epitope(s).
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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METHOD DETAILS
HA Expression and Purification rHA ''head'' and rHA full length soluble ectodomains (FLsE) constructs were cloned into pFastBac vector for insect cell expression (Hi5 cells) or pVRC vector for mammalian expression (293F or 293S cells). All constructs were confirmed by DNA sequencing at the DNA Sequencing Core Facility at Dana Farber Cancer Institute. For biolayer interferometry (BLI) and crystallography the HA1 head constructs contained a HRV 3C-cleavable C-terminal His 6X tag or SBP-His 8X tag. The HA FLsE constructs used in ELISA assays contained a thrombin or HRV 3C-cleavable C-terminal foldon tag with either a His 6X or SBP-His 8X tag. All constructs were purified from supernatants by passage over Cobalt-TALON resin (Takara) followed by gel filtration chromatography on Superdex 200 Increase (GE Healthcare) in 10 mM Tris-HCl, 150 mM NaCl at pH 7.5. Affinity tags were removed using HRV 3C protease (ThermoScientific) and the protein repurified using Cobalt-TALON resin to remove the protease, tag and non-cleaved protein.
Fab and IgG Expression and Purification
For Fab and IgG production the genes for the heavy-and light-chain variable domains were synthesized and codon optimized by Integrated DNA Technologies and subcloned into pVRC protein expression vectors containing human heavy-and light-chain constant domains ( (Schmidt et al., 2015a; Schmidt et al., 2015b) ). Constructs were confirmed by sequencing at the DNA Sequencing Core Facility at Dana Farber Cancer Institute. Fabs and IgGs were produced by transient transfection in suspension 293F cells using polyethylenamine (PEI). Supernatants were harvested 4-5 days later, clarified by centrifugation. Fabs were purified using Cobalt-TALON resin (Takara) followed by gel filtration chromatography on Superdex 200 Increase (GE Healthcare) in 10 mM Tris-HCl, 150 mM NaCl at pH 7.5. IgGs were purified using Protein G Plus Agarose (ThermoFisher Scientific). Briefly, IgG supernatants were incubated overnight with agarose slurry, eluted with 0.1M glycine, pH 2.5 and normalized with 1M Tris-HCl, pH 8.0 and dialyzed against PBS buffer overnight.
ELISA 5-10ng of rHA FLsE were adhered to high-capacity binding, 96 well-plates (Corning) overnight in PBS. Plates were blocked with nonfat dried milk in PBS containing Tween-20 (PBS-T) for 1hr at room temperature (RT). Blocking solution was discarded and 10-fold dilutions of RBS-directed IgGs in PBS were added to wells and incubated for 1hr at RT. Plates were then washed three times with PBS-T. Secondary, anti-human IgG-HRP (Abcam), in PBS-T was added to each and incubated for 1hr at RT. Plates were then washed three times with PBS-T. Plates were developed using 1-Step ABTS substrate (ThermoFisher) and immediately read using a plate reader at 410nm. Data were plotted using Prism 6 (GraphPad Software) and affinities determined. For intact virion binding, the 96 well-plates were coated (in two replicates) with 50 ml of H3N2 A/Aichi/2/1968 (X31) virus (Charles River) at 10 mg/ml for 2 hours at room temperature (RT) in PBS. Plates were blocked with 2% BSA in PBS for 1 hour at RT. Blocking solution was discarded and triplicates of 5-fold dilutions of human IgG1 mAbs HC19, FI6v3 and FL-1066 in blocking solution were added to wells and incubated for 1hr at RT. Plates were then washed three times with PBS. Secondary, anti-human IgG-HRP (1:10000 dilution, Abcam 97225), in PBS was added and incubated for 30 min at RT. Plates were then washed three times with PBS and developed using 1-Step Ultra TMB substrate (ThermoFisher) The reaction stopped with 2M sulfuric acid and absorbance at 450nm read using a plate reader.
Cell-Surface HA Staining Human HEK293S cells were transiently transfected with the modified pVRC8400 expression vectors into which full-length HAs were cloned (Schmidt et al., 2015b ) using polyethylenimine (PEI). Transfection complexes were prepared in Opti-MEM and added to cells. At 24 hours post transfection, cells were harvested for staining. The cells were pelleted at 200 g and washed with phosphate buffered saline (PBS) pH 7.4 supplemented with 1mM EDTA, 0.5% BSA (FACS buffer). 50,000 cells were then incubated for 30 minutes on ice with primary antibody (human IgG1) at a range of concentrations 0.045-100nM in FACS buffer. Cells were washed three times in FACS buffer and incubated with goat anti-human IgG antibody conjugated with A488 (1:500 dilution, Thermo Scientific CAT#A11013) and eFluorÒ 780 Fixable Viability Dye (1:2000 dilution, Thermo Scientific CAT#65-0865-14) for 30 minutes on ice. The cells were washed and resuspended in the FACS buffer. Fluorescence was measured using a BD FACSCanto equipped with HTS and analyzed using FlowJo software (FlowJo Inc, Ashland, OR). ) and plasmablasts/-cytes (B220 lo CD138 hi ) cells in popliteal LNs were determined as described (Reynolds et al., 2015; Kuraoka et al., 2016) . Labeled cells were analyzed/sorted in a FACS Canto (BD Bioscience) or a FACS Vantage with DIVA option (BD Bioscience). Flow cytometric data were analyzed with FlowJo software (Treestar Inc.). Doublets were excluded by FSC-A/FSC-H gating strategy. Cells that took up propidium iodide were excluded from our analyses.
Flow Cytometry
Nojima Cultures
Single B cell cultures were performed as described (Kuraoka et al., 2016) . Briefly, single GC B cells were cultured for 10 days in the presence of NB-21.2D9 feeder cells. After culture, culture supernatants were harvested for Luminex determinations and culture plates were stored at -80 C for V(D)J amplifications.
Luminex Multiplex Assay
Reactivity of clonal IgGs in culture supernatants and mouse sera was determined by Luminex multiplex assay (Kuraoka et al., 2016; McCarthy et al., 2018) . Mixtures of antigen-conjugated microspheres were incubated with 1:10 diluted culture supernatant samples or with serially diluted serum samples for 2 hours at room temperature with mild agitation. Samples were diluted in PBS containing 1% cow milk, 1% BSA, 0.05% Tween 20 and 0.05% NaN 3 . After washing, PE goat anti-mouse IgG (Southern Biotech) was added to the plates and incubated for 1 hour at room temperature with mild agitation. After washing, microspheres were resuspended in PBS containing 1% BSA, 0.05% Tween 20 and 0.05% NaN 3 and fluorescent signals from each microsphere were measured in a Bio-Plex Ò 3D machine (Bio-Rad).
BCR Repertoire Analysis V(D)J rearrangements of cultured B cells were amplified by a nested PCR, cloned, and sequenced as previously described (Kuraoka et al., 2016) . The rearranged V, D, and J gene segments were identified using IMGT/V-QUEST (http://www.imgt.org/) or Cloanalyst (Kepler, 2013) .
